Q-omics provides the consensus-scored HNRNPD profile across patient tissues and cancer cell-line models. HNRNPD expression is associated with patient survival in 28 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, HNRNPD is differentially expressed in 12, with the highest sampling consensus in HNSC. Additionally, HNRNPD protein abundance shows 24,974 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight ACC, HNSC, and GBM as cancer lineages where HNRNPD shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for HNRNPD — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes HNRNPD survival associations across molecular data types. HNRNPD RNA expression shows survival associations in the most cancer types (28), followed by mutation status (3) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible HNRNPD RNA expression–survival associations across cancer types. High HNRNPD expression shows unfavorable associations in ACC, KIRP, LIHC and LGG, but favorable associations in BRCA and KIRC. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for HNRNPD RNA expression.
This table summarizes HNRNPD tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 9. The strongest signals are observed in KIRC for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for HNRNPD. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. HNRNPD shows higher tumor expression in HNSC, COAD, KIRC, STAD, LIHC and LUSC. The HNSC box plot shows higher HNRNPD RNA expression in tumor versus normal tissue (log2 FC = +0.936, t-test p < 0.001).
This table shows molecular features associated with HNRNPD in patient tissues and cancer cell lines. In patient samples, HNRNPD shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, HNRNPD RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN, while CRISPR and shRNA rows add functional-dependency signals in OVARY and BLOOD_Leukemia.
